Katznelson S, Gjertson D W, Cecka J M
UCLA Tissue Typing Laboratory, Los Angeles, California, USA.
Clin Transpl. 1995:379-94.
Asian recipients of cadaveric renal allografts had the best long-term survival rates. Five-year graft survival rates were 66% for 1,713 Asians, 61% for 4,722 Hispanics and 33,190 Whites, and 47% for 12,948 Blacks. This trend had already been established at one-year posttransplant. Transplant half-lives calculated after 6 months were 12 years for Asians, 10 years for Whites, 9 years for Hispanics and 5 years for Blacks. These have all improved over the last 4 years. Part of the explanation for the outstanding half-life for Asian recipients is the 15 year half-life of the 672 Asian females reported. The superior graft survival for Asian recipients may be due in part to the low incidence of sensitization, the low incidence of acute rejection and chronic rejection leading to graft loss, and the high prevalence of primary disease entities that have been associated with excellent long-term prognoses, especially IgA nephropathy and chronic glomerulonephritis. Hispanic recipients also had excellent short- and long-term graft survival rates. This may be due to having the lowest incidence of early acute rejection episodes compared with all other racial groups, and the limited deleterious effect of ATN on long-term graft survival among Hispanics. The poor overall graft survival for Black recipients may be due to poor HLA matching, a high rate of sensitization and a grim effect of sensitization on graft survival, the high incidences of acute rejection and ATN, and the high incidence of HTN both pre- and posttransplant. The only subgroups of Black recipients who had graft survival rates that were comparable to other racial groups were the zero-HLA-mismatched Black recipients and those Black recipients over age 65. Long-term patient survival rates were the best for Asians and Hispanics (89% and 90% at 5 years, respectively). The 5-year patient survival rates were lower for Blacks and Whites (86% each). There was no difference in patient survival at one-year posttransplant (95-96% for each group). A higher proportion of White diabetic recipients received simultaneous SPK transplants (31%) than Black (10%), Hispanic (11%) or Asian (7%) diabetics. The reasons for this disparity are unclear. However, SPK transplants improved 5-year kidney graft survival for Whites (67% vs 55% in patients receiving kidneys alone), but were not associated with improved 5-year kidney survival among non-Whites. White donors accounted for the majority of all transplanted organs (79%). Matching donor and recipient race ("race matching") led to better long-term allograft survival for White recipients only. There was no donor-recipient "race matching" effect for minority groups.
亚洲尸体肾移植受者的长期存活率最高。1713名亚洲人的5年移植肾存活率为66%,4722名西班牙裔和33190名白人的为61%,12948名黑人的为47%。这种趋势在移植后1年时就已确立。6个月后计算得出的移植肾半衰期,亚洲人为12年,白人为10年,西班牙裔为9年,黑人为5年。在过去4年里这些数据都有所改善。亚洲受者移植肾半衰期出色的部分原因在于所报告的672名亚洲女性的移植肾半衰期为15年。亚洲受者移植肾存活率较高可能部分归因于致敏发生率低、导致移植肾丢失的急性排斥和慢性排斥发生率低,以及与良好长期预后相关的原发性疾病实体患病率高,尤其是IgA肾病和慢性肾小球肾炎。西班牙裔受者的短期和长期移植肾存活率也很高。这可能是因为与所有其他种族群体相比,其早期急性排斥反应发作的发生率最低,且急性肾小管坏死对西班牙裔受者长期移植肾存活的有害影响有限。黑人受者总体移植肾存活率低可能是由于HLA配型不佳、致敏率高以及致敏对移植肾存活的严重影响、急性排斥和急性肾小管坏死的高发生率,以及移植前后高血压的高发生率。移植肾存活率与其他种族群体相当的黑人受者亚组仅为HLA错配为零的黑人受者以及65岁以上的黑人受者。亚洲人和西班牙裔的长期患者存活率最高(5年时分别为89%和90%)。黑人和白人的5年患者存活率较低(均为86%)。移植后1年时患者存活率无差异(每组均为95 - 96%)。接受同期胰肾联合移植(SPK)的白人糖尿病受者比例(31%)高于黑人(10%)、西班牙裔(11%)或亚洲(7%)糖尿病患者。这种差异的原因尚不清楚。然而,SPK移植改善了白人的5年肾移植存活率(接受单纯肾移植的患者为55%,接受SPK移植的患者为67%),但与非白人的5年肾存活率提高无关。白人供者占所有移植器官的大多数(79%)。供受者种族匹配(“种族匹配”)仅使白人受者的长期同种异体移植存活率更高。少数群体不存在供受者“种族匹配”效应。